Obstructive sleep apnoea syndrome in patients living with diabetes: which patients should be screened?

CONCLUSION: The high prevalence of OSAS in patients with T1D and T2D justifies screening for the syndrome, which should be based on clinical symptoms, as the benefits of OSAS treatment are mainly improvement of symptoms related to sleep apnoea. There are also several clinical situations wherein screening for OSAS seems justified in diabetes patients even when they have no symptoms, particularly to optimalize control of blood pressure in cases of resistant hypertension and microvascular complications. PMID: 30189344 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/30189344?dopt=Abstract

Source: Diabetes and Metabolism - September 3, 2018 Category: Endocrinology Authors: Borel AL, Tamisier R, Böhme P, Priou P, Avignon A, Benhamou PY, Hanaire H, Pépin JL, Kessler L, Valensi P, Darmon P, Gagnadoux F Tags: Diabetes Metab Source Type: research